What is Acumen Pharmaceuticals Inc's share price today?
Acumen Pharmaceuticals Inc (ABOS) share price today is $0.21 as of November 6, 2026 at 10:13 PM IST. The stock touched a day high of $0.22 and a day low of $0.21.What exchange does Acumen Pharmaceuticals Inc stock trade on, and under what ticker symbol?
Acumen Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol ABOS.What is Acumen Pharmaceuticals Inc's market capitalization?
Acumen Pharmaceuticals Inc's market capitalization is $15.64M as of November 6, 2026 at 10:13 PM IST.What is Acumen Pharmaceuticals Inc's price-to-earnings (P/E) ratio?
Acumen Pharmaceuticals Inc's price-to-earnings (P/E) ratio is N/A as of November 6, 2026.What is Acumen Pharmaceuticals Inc's price-to-book (P/B) ratio?
Acumen Pharmaceuticals Inc's price-to-book (P/B) ratio is 0.48 as of November 6, 2026.Can Indian investors buy Acumen Pharmaceuticals Inc shares?
Yes, You can buy Acumen Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.How can I invest in Acumen Pharmaceuticals Inc shares from India?
Indian investors can buy Acumen Pharmaceuticals Inc shares in three steps: 1. Search Acumen Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.How does USD-INR currency movement affect returns from Acumen Pharmaceuticals Inc shares for Indian investors?
Since Acumen Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.What is the minimum amount required to invest in Acumen Pharmaceuticals Inc shares via Tickertape?
Indian investors can start investing in Acumen Pharmaceuticals Inc (ABOS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 46.0829 shares at the current price of $0.21.
$
₹
$0.211.49% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max
Key Metrics
Key Metrics
PE TTM
PE TTM
Close price divided by the earnings per share for the trailing twelve months
—
PB
PB
Close price divided by the book value per share at the end of the most recent quarter
0.48
EPS TTM
EPS TTM
Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)
$-1.55
PEG Ratio
PEG Ratio
Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years
—
Profit Margin
Profit Margin
Net profit divided by the total revenue for the most recent financial year
0%
Dividend Yield
Dividend Yield
Annual dividend per share for the trailing twelve months divided by the close price
—
Based on 6 analysts reports
Buy6 analysts
Hold0 analyst
Sell0 analyst
Price Upside
+362.32%
Earnings Growth
+19.98%
Rev. Growth
—
Company Profile
Company Profile
ABBV
P/E Ratio
50.65
50.65
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
AMGN
P/E Ratio
27.73
27.73
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
P/E Ratio
35.33
35.33
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
P/E Ratio
20.57
20.57
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Forecast
Forecast
Price
Revenue
Earnings
Price Forecast
Price Forecast
2026
Current$0.22Baseline
Analyst Target - 1 year
Target$1+362.32%
All values in $
2026
Current$0.22Baseline
Analyst Target - 1 year
Target$1+362.32%
All values in $
Earnings Per Share Forecast
Earnings Per Share Forecast
2025
Current$-2.01Baseline
Forecast for Dec 2026
High$-1.5+25.37%
Average$-1.61+19.98%
Low$-1.72+14.65%
All values in $
2025
Current$-2.01Baseline
Forecast for Dec 2026
High$-1.5+25.37%
Average$-1.61+19.98%
Low$-1.72+14.65%
All values in $
Financials
Financials
Income
Balance Sheet
Cash Flow
Quarterly Normal View
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
| Financial Year | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0.17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -0.04 | -0.04 | -0.04 | -0.04 | - | - | -0.04 | -0.04 | - | - |
| Net Income | -20.53 | -29.76 | -37.15 | -28.79 | -40.95 | -26.45 | -25.13 | -20.73 | -32.71 | -25.36 |
| Net Profit Margin | - | - | -20873.03% | - | - | - | - | - | - | - |
Peers
Peers & Comparison
Peers & Comparison
Comparing 2 stocks from
HealthcareBiotechnology
HealthcareBiotechnology
Valuation
Returns
Forecast
| Stock | PE TTMPE TTM | PBPB | PEG RatioPEG Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals Inc | - | 0.48 | - |
| AbbVie Inc | 50.65 | 50.45 | 0.58 |
| Amgen Inc | 27.73 | 21.33 | 2.75 |
Price Comparison
Price Comparison
Compare ABOS with any stock or ETFCompare ABOS with any stock or ETF
Comparing from
ABOS
ABBV
AMGN
The 12-month consensus target implies 362.32% growth, versus a trailing 3-year CAGR of -52.97%.